Despite an adequate and safe blood supply in North America and Europe, the pursuit of an artificial blood substitute remains noble if 3 conditions are met: it is safe, effective, and universally available. In this issue of JAMA, the findings of Natanson and colleagues1 of a clinically important increase in risk of mortality and risk of myocardial infarction across hemoglobin-based oxygen carrier (HBOC) trials cast serious doubt on the first and second conditions, thereby making the third irrelevant. Specifically, based on their analysis of available data, the authors found a 30% increase in the risk of death and nearly a 3-fold increase in risk of myocardial infarction when all HBOC trials were pooled. More troubling, trials continue to be planned and conducted in the presence of accumulating knowledge as demonstrated by the cumulative meta-analyses.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 15
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.